Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Multiple solid tumors
PULSO Trial: Evaluating Pulsed Low-Dose-Rate Radiation for Esophageal Cancer
The Medical College of Wisconsin is running a phase 2 randomized trial comparing pulsed low-dose-rate radiation to standard chemoradiation in patients with advanced/metastatic esophageal cancer. Both arms include…
NCT06906887 - New trial
Multiple solid tumors
Phase 1 Study Evaluates HCB301 in Advanced Solid Tumors and Refractory cHL
FBD Biologics is assessing the safety, pharmacokinetics, and preliminary efficacy of HCB301 administered via IV across escalating doses (0.3 to 15.0 mg/kg) in patients with advanced solid tumors or…
NCT06487624 - New trial
Multiple solid tumors
Pilot Study Evaluates 68Ga-FAPI-46 PET/CT for Tumor Microenvironment Assessment
Vanderbilt University is conducting a pilot study in solid tumor patients scheduled for antibody-based therapy to compare 68Ga-FAPI-46 PET/CT imaging with standard MRI/CT scans. This trial involves a single IV dose…
NCT06922825 - New trial
Multiple solid tumors
Phase 1b/2 Study Evaluates WTX-330 Dosing Regimens in Advanced Solid Tumors and NHL
Werewolf Therapeutics is assessing WTX-330, an IL-12 peptide prodrug, using both fixed and step-up dosing regimens in a multisite study targeting advanced/metastatic solid tumors and non-Hodgkin lymphoma. The trial…
NCT06939283 - New trial
Multiple solid tumors
Phase I/II Study Explores MT-4561 in Advanced Solid Tumors and Drug-Drug Interaction
Mitsubishi Tanabe Pharma America is launching a first-in-human, open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-4561 in patients with various advanced solid…
NCT06943521 - New trial
Multiple solid tumors
Phase 1/2 Trial Evaluates Neratinib Plus Valproic Acid in Advanced Solid Tumors with RAS Focus
Virginia Commonwealth University is testing a combination of neratinib—a HER2/HER4/EGFR inhibitor—and divalproex sodium in advanced solid tumors, with particular attention to RAS-mutated cancers, EGFR-altered…
NCT03919292 - New trial
Multiple solid tumors
Phase 1a/1b Trial Investigates Intrathecal Deferoxamine for Leptomeningeal Metastases
Memorial Sloan Kettering is evaluating the safety, pharmacokinetics, and pharmacodynamics of intrathecal deferoxamine in patients with leptomeningeal metastases from solid tumors, including NSCLC. This open-label,…
NCT05184816 - New trial
Multiple solid tumors
Perioperative Chemoimmunotherapy with Toripalimab for Sinonasal Cancer
Dana Farber is investigating a novel perioperative regimen combining toripalimab with docetaxel and carboplatin preceding surgery for resectable sinonasal cancers, including undifferentiated carcinoma and squamous…
NCT06940180 - New trial
Multiple solid tumors
Phase 1/2 Trial Assesses Inhaled Oncolytic Virus KB707 in Lung Cancer
Krystal Biotech is evaluating KB707—a replication-defective, HSV-1-derived vector expressing IL-2 and IL-12—administered via nebulization in advanced solid tumor malignancies affecting the lungs. The study includes…
NCT06228326 - New trial
Multiple solid tumors
Phase I/II Study of 225Ac-SSO110 Combined with SoC in SSTR2+ ES-SCLC and Merkel Cell Carcinoma
Ariceum Therapeutics is investigating the safety, tolerability, RP2D, and preliminary efficacy of 225Ac-SSO110 in combination with standard of care—including checkpoint inhibitors and chemotherapy—in patients with…
NCT06939036 - New trial
Multiple solid tumors
Phase I/II Trial Evaluates DM002 in Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) is conducting a first-in-human, open-label study to assess the safety, pharmacokinetics, and preliminary efficacy of DM002 in advanced solid tumors. The study features a…
NCT06751329 - New trial
Multiple solid tumors
Phase 1 Trial Investigates MRTX1719 in MTAP-Deleted Advanced Solid Tumors
Bristol-Myers Squibb is conducting an open-label, multicenter study to assess the safety, PK/PD, and antitumor activity of MRTX1719—a PRMT5 inhibitor—in patients with unresectable or metastatic solid tumors harboring…
NCT06937970 - Trial result
Other blood cancers and transplant
INCB057643 Rebalances Bone Marrow in MPNs by Shifting Megakaryopoiesis Toward Erythropoiesis
Preclinical data using a patient-derived xenograft model and clinical analyses from MPN patients treated with INCB057643 demonstrated that this BET inhibitor reduces JAK2 V617F+ stem cells and dysplastic…
- Trial result
Other blood cancers and transplant
TP-0903 Shows Early Signs of Activity in Heavily Pretreated FLT3-ITD AML Patients
In a phase 1b/2 trial, three relapsed/refractory AML patients with FLT3-ITD mutations were treated with oral TP-0903, starting at 50 mg daily—with dose reduction to 37 mg for one patient due to manageable grade 3…
- Trial result
Other blood cancers and transplant
Novel Immunotherapy Combo Yields High Response Rates in Non-Fit Frontline AML Patients
In the AARON phase I/II trial, frontline non-fit AML patients with adverse risk profiles treated with azacitidine/venetoclax plus dual checkpoint blockade using nivolumab (anti-PD-1) and relatlimab (anti-LAG-3)…
- Trial result
Other blood cancers and transplant
SENTI-202’s Dual-Targeting CAR NK Cell Therapy Shows Promising AML Activity and Hematopoietic Recovery
In a Phase I study of relapsed/refractory AML, SENTI-202—a logic gated CAR NK cell therapy targeting both CD33 and FLT3 while sparing EMCN+ healthy HSPCs—demonstrated marked blast reduction with MRD-negative complete…
- New trial
Other blood cancers and transplant
TCR α/β Depleted PBSC Transplantation in Inherited Bone Marrow Failure Disorders
This phase II trial at the Masonic Cancer Center investigates T cell receptor α/β depletion in PBSC transplantation for patients with inherited bone marrow failure syndromes, aiming to eliminate routine GVHD…
NCT03579875 - New trial
Other blood cancers and transplant
Phase II MeziKD Combines Novel Agents in Relapsed/Refractory MM with Extramedullary Disease
Roswell Park Cancer Institute is evaluating a regimen of mezigdomide, carfilzomib, and dexamethasone to target relapsed/refractory multiple myeloma with extramedullary disease. This trial leverages a cereblon…
NCT06627751 - New trial
Other blood cancers and transplant
Phase II Dasatinib & Quercetin with CAR-T Therapy in Advanced Multiple Myeloma
Mayo Clinic is investigating a regimen combining dasatinib and quercetin with preconditioning chemotherapy and CAR-T cell therapy for patients with relapsed/refractory multiple myeloma on fourth-line treatment and…
NCT06940297 - New trial
Other blood cancers and transplant
First-in-Human Phase I Study of SAR446523 in Relapsed/Refractory Multiple Myeloma
Sanofi is assessing subcutaneous SAR446523, an anti-GPRC5D ADCC-enhanced monoclonal antibody, in a first-in-human study of heavily pretreated MM patients. The trial will determine the safety profile,…
NCT06630806 - New trial
Other blood cancers and transplant
Phase I Master Protocol Evaluates BCMA-Directed CAR-T Therapies in R/R MM
Kite, a Gilead Company, is running a proof-of-concept master protocol to assess BCMA-specific CAR-T cell therapies—featuring an alternative binding domain—in patients with relapsed/refractory multiple myeloma, with…
NCT04155749 - New trial
Other blood cancers and transplant
Phase 1b/2a Study Evaluates SNIPR001 with Levofloxacin in HSCT Patients Harboring FQR E. coli
SNIPR Biome Aps. is investigating the safety, PK/PD, and preliminary efficacy of SNIPR001 administered with standard levofloxacin in allogeneic HSCT recipients colonized with fluoroquinolone-resistant E. coli. This…
NCT06938867 - New trial
Other blood cancers and transplant
Phase 1/2 Study of Tuspetinib (HM43239) in AML, MDS, and CMML
Aptose Biosciences Inc. is exploring the safety, tolerability, and optimal dosing of tuspetinib—with or without venetoclax (±azacitidine)—in patients with relapsed/refractory AML, MDS-IB2, CMML, and newly diagnosed…
NCT03850574 - New trial
Other blood cancers and transplant
Phase I Post-Transplant Maintenance with Tagraxofusp in CD123+ Myeloid Disorders
The University of Virginia is investigating escalating doses of tagraxofusp—a diphtheria toxin-IL3 fusion protein—as maintenance therapy post-allogeneic HCT in patients with CD123+ AML, CMML, and myelofibrosis.…
NCT05233618 - New trial
Other blood cancers and transplant
Phase II MyeloMATCH Trial Examines ASTX727 ± Enasidenib in Higher-Risk IDH2-Mutated MDS
The National Cancer Institute is comparing cedazuridine-decitabine (ASTX727) alone versus its combination with enasidenib in treatment-naïve, higher-risk IDH2-mutated MDS patients. This study evaluates whether adding…
NCT06577441 - New trial
Other blood cancers and transplant
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics is assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral AUTX-703 in a multicenter dose escalation and optimization trial for patients with relapsed/refractory AML and…
NCT06846606 - New trial
Other blood cancers and transplant
Phase Ib/II Venetoclax Plus Vincristine in Relapsed/Refractory Lymphoid Malignancies
ECOG-ACRIN is investigating the safety, tolerability, and efficacy of combining venetoclax with either liposomal or sulfate vincristine in patients with relapsed/refractory acute lymphoblastic leukemia and…
NCT03504644 - New trial
Other blood cancers and transplant
Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Eli Lilly’s master protocol is designed to assess the long-term safety and efficacy of pirtobrutinib in participants from prior originator studies. This framework, using individual study-specific appendices, enables…
NCT06876649
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.